Pharmacy Website
Clinic Website

Intelligence » Leukemia » Last Week

Subscribe to get latest posts via email or subscribe to a RSS feed.

Novel Subtypes in B Progenitor Acute Lymphoblastic Leukemia

Wednesday, December 12, 2018 -- MedicalResearch.comInterview with: Zhaohui Gu, PhDPostdoctoral Research Associate St. Jude Children’s Research Hospital, TN  What is the background for this study?  What are the main findings? Response:B-progenitor acute lymphoblastic leukemia (B-ALL) is the most common pediatric malignancy and the leading cause of … Continue reading →

Unrelated donor vs HLA-haploidentical {alpha}/{beta} T-cell- and B-cell-depleted HSCT in children with acute leukemia

Thursday, December 13, 2018 -- Traditionally, hematopoietic stem cell transplantation (HSCT) from both HLA-matched related and unrelated donors (UD) has been used for treating children with acute leukemia (AL) in need of an allograft. Recently, HLA-haploidentical HSCT after αβ T-cell/B-cell depletion (αβhaplo-HSCT) was shown to be effective in single-center studies. Here, we report the first multicenter retrospective analysis of 127 matched UD (MUD), 118 mismatched UD (MMUD), and 98 αβhaplo-HSCT recipients, transplanted between 2010 and 2015, in 13 Italian centers. All these AL children were transplanted in morphological remission after a myeloablative conditioning regimen. Graft failure occurred in 2% each of UD-HSCT and αβhaplo-HSCT groups. In MUD vs MMUD-HSCT recipients, the cumulative incidence of grade II to IV and grade III to IV acute

AstraZeneca kicks off second blood cancer launch, this time for orphan drug Lumoxiti

Wednesday, December 12, 2018 -- For the second straight year, AstraZeneca is spending the fall launching a hemo-oncology drug. Lumoxiti, a treatment for the rare disease hairy cell leukemia, is rolling out to patients after a Sept. 14 FDA approval, with AZ initially targeting 10-15 high-priority clinics.